OMA Vendor Directory
Find great resources for your obesity medicine practice.
Search the Obesity Medicine Association’s Vendor Directory to find the right resources for your practice. Vendors listed offer a variety of products, services, technologies, and solutions for your obesity medicine practice.
Disclaimer: The Obesity Medicine Association (OMA) presents a forum for its members to be exposed to various products and services. It is the responsibility of each member to do due diligence, including reviewing literature, lectures, and background information. The individual is also responsible for becoming familiar with laws on prescribing limitations within his or her own state before practicing various therapies. OMA does not endorse, approve, or sponsor any products or services.
Browse by Category:
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Viking’s lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being evaluated in a Phase 3 obesity program (VANQUISH-1 and VANQUISH-2) after demonstrating encouraging safety, tolerability, and clinical benefit in earlier trials. The company is also advancing an oral formulation of VK2735. Viking’s second program, VK2809, a selective thyroid hormone receptor beta agonist, achieved significant efficacy in Phase 2 studies for NASH, NAFLD, and dyslipidemia. Viking’s pipeline additionally includes dual amylin and calcitonin receptor agonists (DACRAs) for obesity and VK0214 for X-linked adrenoleukodystrophy, which showed favorable safety and reduced very long-chain fatty acids in Phase 1b. Learn more at www.vikingtherapeutics.com.
Showing 11-11 of 11 results
Vendor Directory Listing
Submit your application for your organization to be listed in the Vendor Directory. Organizations are listed in the online directory and included in the monthly OMA newsletter.